Matinas BioPharma Holdings, Inc. specializes in the discovery and development of various product candidates using its lipid nanocrystal platform technology. Their LNC delivery technology utilizes lipid nano-crystals for the delivery of a range of treatments, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. The company's lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition used to treat cardiovascular and metabolic conditions, with other promising products in the pipeline.